On May 4, 2022, the Food and Drug Administration (FDA) approved Enhertu (trastuzumab deruxtecan) treatment from Daiichi Sankyo Company and AstraZeneca, for adult patients with unresectable or metastatic HER2-positive breast cancer who have previously received two or more treatment regimens based on anti-HER2 therapies. The treatment is approved in the metastatic setting or in the neoadjuvant or adjuvant setting, and for those patients who have developed disease recurrence during or within 6 months after completion of treatment.
FDA APPROVES TRASTUZUMAB DERUXTECAN FAM-TRASTUZUMAB DERUXTECAN-NXKI FOR BREAST CANCER
Share
Share on facebook
Share on linkedin
Share on twitter
Share on email